title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M,20220516T135412,https://www.benzinga.com/general/biotech/22/05/27220874/chimerix-shares-plummet-after-divesting-its-only-marketed-product-for-over-300m,SYMQY,0.149842,Neutral,0.016097
"Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA®  ( brincidofovir ) , the First FDA-Approved Smallpox Oral Antiviral for All Ages",20220516T103217,https://www.benzinga.com/pressreleases/22/05/g27214216/emergent-biosolutions-to-acquire-from-chimerix-its-exclusive-worldwide-rights-to-tembexa-brincidof,SYMQY,0.026207,Neutral,0.001206
"Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA®  ( brincidofovir ) , the First FDA-Approved Smallpox Oral Antiviral for All Ages",20220516T103200,https://www.globenewswire.com/news-release/2022/05/16/2443624/33240/en/Emergent-BioSolutions-to-Acquire-from-Chimerix-its-Exclusive-Worldwide-Rights-to-TEMBEXA-brincidofovir-the-First-FDA-Approved-Smallpox-Oral-Antiviral-for-All-Ages.html,SYMQY,0.027379,Neutral,0.004035
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties,20220516T103000,https://www.globenewswire.com/news-release/2022/05/16/2443619/25619/en/Chimerix-Announces-Sale-of-TEMBEXA-to-Emergent-BioSolutions-for-up-to-337-5-Million-plus-Royalties.html,SYMQY,0.041075,Neutral,0.008342
